John Rush has more than 28 years of experience in the medical device sector, and joined Inova Labs as Chief Executive Officer in 2011. Previously, Rush served as Chief Executive Officer of U.K. – based Lombard Medical Technologies PLC, a medical device company for the abdominal aortic aneurysm repair market, from 2009 to early 2011. Currently, Rush also serves as non-executive Chairman of the Lombard Medical Board of Directors. During his tenure at Lombard, the Company successfully navigated through an IDE PMA trial in the United States which led to FDA approval for it’s AAA stent graft in early 2013. Before joining Lombard, Rush was President and CEO of North American Scientific, Inc. (NASDAQ: NASM) where he re-organized the company and led an investor group initiative to take part of the company private. Rush also served as President and CEO of MicroTherapeutics, Inc. (NASDAQ:MTIX), an interventional neuroradiology company with operations in the United States and Europe. He orchestrated a successful sale of the company to ev3. Prior to MTIX, Rush spent 10 years with Scimed Life Systems/Boston Scientific in various management roles, including General Manager of Boston Scientific’s Asia Pacific business based in Singapore. Rush has extensive domestic and international experience, with a core sales and marketing background.